scholarly journals FDA Issues Safety Alert for Hypodermic Needles on Secondary IV Administration Sets

1992 ◽  
Vol 13 (6) ◽  
pp. 373-373
Author(s):  
Elaine Larson
Keyword(s):  
2005 ◽  
Vol 35 (23) ◽  
pp. 9
Author(s):  
Miriam E. Tucker
Keyword(s):  

Author(s):  
Parshal Chitrakar ◽  
Yoganand Biradavolu ◽  
Siva Sankar Yellampalli
Keyword(s):  

2020 ◽  
Vol 3 (2) ◽  
pp. 114-119
Author(s):  
Samsudin Samsudin ◽  
Muhammad Ikhsan ◽  
Maya Juliana Ritonga

The research purpose to design a motorcycle safety alert system using ultrasonic sensors to detect objects within reach and using the microcontroller as the brain of the process control system so that it can be used to build electrical systems. The bike's safety-distance warning system uses fuzzy logic in the soft computing category, a method that could process uncertain, inaccurate, and less cost implemented data. With this system, it can help the community to reduce the number of a road accident to generate output in some conditions such as safe, carefully, and dangerous by using alarm warnings that can cause sound and LED as virtual and LCD notifications that can display distances in efficient and effective. Based on the results of the tests being done, the sensor system is accurate at 95.242% at 10 times the test.


2018 ◽  
Vol 2018 ◽  
pp. 1-17 ◽  
Author(s):  
Sheeraz Ahmed ◽  
Mujeeb Ur Rehman ◽  
Atif Ishtiaq ◽  
Sarmadullah Khan ◽  
Armughan Ali ◽  
...  

VANET is an application and subclass of MANETs, a quickly maturing, promising, and emerging technology these days. VANETs establish communication among vehicles (V2V) and roadside infrastructure (V2I). As vehicles move with high speed, hence environment and topology change with time. There is no optimum routing protocol which ensures full-pledge on-time delivery of data to destination nodes, and an absolutely optimum scheme design for flawless packet exchange is still a challenging task. In VANETs, accurate and on-time delivery of fundamental safety alert messages (FSAMs) is highly important to withstand against maliciously inserted security threats affectively. In this paper, we have presented a new security-aware routing technique called VANSec. The presented scheme is more immune and resistive against different kinds of attacks and thwarts malicious node penetration attempts to the entire network. It is basically based on trust management approach. The aim of the scheme is to identify malicious data and false nodes. The simulation results of VANSec are compared with already existing techniques called trust and LT in terms of trust computation error (TCE), end-to-end delay (EED), average link duration (ALD), and normalized routing overhead (NRO). In terms of TCE, VANSec is 11.6% and 7.3% efficient than LT and trust, respectively, while from EED comparison we found VANSec to be 57.6% more efficient than trust and 5.2% more efficient than LT. Similarly, in terms of ALD, VANSec provides 29.7% and 7.8% more stable link duration than trust and LT do, respectively, and in terms of NRO, VANSec protocol has 27.5% and 14% lesser load than that of trust and LT, respectively.


2020 ◽  
Vol 11 ◽  
pp. 204209862090961
Author(s):  
Marina A. Malikova

Pharmacovigilance is a field where communication is crucial, and exchange of information is expected to be done in a timely manner. Information from individual case reports is transmitted from pharmaceutical industry and health professionals to the regulatory authorities. The safety profile of a drug is established by analyzing individual cases and aggregate reports. The cumulative information, obtained from these reports, can be used to assist pharmacovigilance professionals in the detection of potential safety signals by monitoring evolving trends. If there is a message identifying concern as potential safety signal, the transmission of individual case reports, as well as cumulative and aggregate reports will occur from pharmaceutical industry to the regulators; and based on their assessments of causality in relationship to the drug, the regulatory decisions will be made. Once regulators confirming a signal as a possible safety alert have made the decision, the decisions and the reasons must be communicated to health professionals, the pharmaceutical industry, and other parties involved (e.g. clinical trials participants, investigators, consumers and medical professionals at post-marketing stage, etc.).


Sign in / Sign up

Export Citation Format

Share Document